Causes and Consequences of Increased Sympathetic Activity in Renal Disease

Hypertension

Volumn 43, Issue 4, 2004, Pages 699-706

  Joles, Jaap A ^a   Koomans, Hein A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antihypertensive agents; Diabetic nephropathy; Hypertension; Renal disease; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; METHYLDOPA; METOPROLOL; MOXONIDINE; NEBIVOLOL; NIPRADILOL; NITRIC OXIDE; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART INJURY; HUMAN; HYPERTENSION; HYPOTHALAMUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; SHORT SURVEY; SYMPATHETIC TONE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSINS; ANIMALS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPOTHALAMUS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; NITRIC OXIDE; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 1642460746     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000121881.77212.b1     Document Type: Short Survey

References (100)

1. Owen WF. Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol. 2003; 14:S76-S80.
2. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14:1535-1548.
3. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int. 2000;58: 1885-1892.
4. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601-1608.
5. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sato W, Morita Y, Maruyama H, Egashira K, Matsuo S. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol. 2003;14:1496-1505.
6. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999:340:1321-1328.
7. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55.
8. Matsumura K, Tsuchihashi T, Fujii K, Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept. 2003;114:79-86.
9. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, Kurnik PB, O'Connor J, Sinha M, Caro JF. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997; 51:1980-1985.
10. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39:1-11.
11. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14:103S-115S
12. Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437-1442.
13. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427-2433.
14. Hausberg M, Kosch M. Hannelink P. Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002:106:1974-1979.
15. Dibona GF, Jones SY, Sawin LL. Reflex influences on renal nerve activity characteristics in nephrosis and heart failure. J Am Soc Nephrol. 1997;8: 1232-1239.
16. Vande Walle JG, Donckerwolcke RA, van Isselt JW, Derkx FH, Joles JA, Koomans HA. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet. 1995; 346:148-152.
17. Faber JE, Brody MJ. Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res. 1985;57: 676-688.
18. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057-1062.
19. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002;15:717-724.
20. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest. 1997;99:540-548.
21. Reid IA. Interactions between ANG 11, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992; 262:E763-E778.
22. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Coma D, Zoja C, Cavallotti D, Rennizzi G. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int. 1997;52:171-181.
23. Wagner L, Riggleman A, Erdely A, Couser W, Baylis C. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int. 2002:62:532-536.
24. Attia DM, Ni ZN, Boer P, Attia MA, Goldschmeding R, Koomans HA, Vaziri ND, Joles JA. Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int. 2002;61:1776-1787.
25. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, Todeschini M, Remuzzi G. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis. 1999;33:746-753.
26. Taal MW, Brenner BM. ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models. J Hum Hypertens. 1999; 13:S51-S56: discussion S61.
27. Atarashi K, Takagi M, Minami M, Ishiyama A. Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats. J Hypertens. 1999;17:1983-1986.
28. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl. 1998;68:S14-S19.
29. Mackie FE, Campbell DJ, Meyer TW. Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int. 2001;59:1458-1465.
30. Verhagen AM, Braam B, Boer P, Grone HJ, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int. 1999;56: 222-231.
31. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol. 1995; 268:H2267-H2273.
32. Togashi H, Sakuma I, Yoshioka M, Kobayashi T, Yasuda H, Kitabatake A, Saito H, Gross SS, Levi R. A central nervous system action of nitric oxide in blood pressure regulation. J Pharmacol Exp Ther. 1992;262:343-347.
33. Dobrucki LW, Cabrera CL, Bohr DF, Malinski T. Central hypotensive action of clonidine requires nitric oxide. Circulation. 2001;104:1884-1886.
34. Matsuoka H, Nishida H, Nomura G, Van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension. 1994;23:971-975.
35. Podjarny E, Benchetrit S, Katz B, Green J, Bernheirn J. Effect of methyldopa on renal function in rats with L-NAME-induced hypertension in pregnancy. Nephron. 2001;88:354-359.
36. Fitzgerald SM, Brands MW. Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system. Am J Physiol Regul Integr Comp Physiol. 2002;282:R1070-R1076.
37. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990;4:1-26.
38. Nakashima A, Matsuoka H, Yasukawa H, Kohno K, Nishida H, Nomura G, Imaizumi T, Morimatsu M. Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nephron. 1996;73:34-40.
39. Tojo A, Kobayashi N, Kimura K, Hirata Y, Matsuoka H, Yagi S, Omata M. Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney. Kidney Int Suppl. 1996;55:S138-S140.
40. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E. Glomerulosclerosis and progression: effect of subanti-hypertensive doses of alpha and beta blockers. Kidney Int. 2001;60: 1309-1323.
41. Fujihara CK, De Lourdes Noronha I, Malheiros, Antunes GR, de Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol. 2000;11: 283-290.
42. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, Ingelfinger JR. Ohno M. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension. 2000;35:800-806.
43. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol. 2002;283:H1577-H1587.
44. Johnson RJ, Gordon KL, Suga S, Duijvestijn AM, Griffin K, Bidani A. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension. 1999;34:151-159.
45. Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant. 2000;15:1735-1748.
46. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11: 1469-1478.
47. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG, Jr., Feuerstein GZ. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Erxp The. 1996;279:948-955.
48. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, Campbell WG, Jr., Barone F, Brooks DP. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol. 2001;134:977-984.
49. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension. 2003;41:201-206.
50. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000;57:1651-1661.
51. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes. Circ Res. 2001;89:815-822.
52. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-816.
53. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-373.
54. Inscho EW. P2 receptors in regulation of renal microvascular function. Am J Physiol Renal Physiol. 2001;280:F927-F944.
55. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
56. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253-307.
57. Schwiebert EM, Kishore BK. Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol. 2001;280:F945-F963.
58. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107: 2747-2752.
59. Attia DM, Verhagen AM, Stroes ES, van Faassen EE, Grone HJ, De Kimpe SJ, Koomans HA, Braam B, Joles JA. Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2001;12:2585-2593.
60. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:P3-P13.
61. Aizawa T, Ishizaka N, Kurokawa K, Nagai R, Nakajima H, Taguchi J, Ohno M. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int 2001;59:645-653.
62. Rodriguez-Perez JC, Losada A, Anabitarte A, Cabrera J, Llobet J, Palop L, Plaza C. Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther. 1997;283: 336-344.
63. Van den Branden C, Gabriels M, Vamecq J, Vanden Houte K, Verbeelen D. Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propanolol. Nephron. 1997;77: 319-324.
64. Takamitsu Y, Nakanishi T, Nishihara F, Hasuike Y, Izumi M, Inoue T, Hiraoka K, Itahana R, Miyagawa K. A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two beta-blocking drugs, nipradilol and propranolol. Nephron Physiol. 2003;93:42-P50.
65. Brooks DP, Short BG, Cyronak MJ, Contino LC, DiCristo M, Wang YX, Ruffolo RR, Jr. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol. 1993;109: 581-586.
66. Erley CM, Rebmann S, Strobel U, Schmidt T, Wehrmann M, Osswald H, Risler T. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol. 1995;3:293-299.
67. Inada H, Ono H, Minami J, Ishimitsu T, Matsuoka H. Nipradilol prevents L-NAME-exacerbated nephrosclerosis with decreasing of caspase-3 expression in SHR. Hypertens Res. 2002;25:433-440.
68. Wangensteen R, O'Valle F, Del Moral R, Vargas F, Osuna A. Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats. Med Sci Monit. 2002;8:BR378-BR384.
69. Kumar KV, Shifow AA, Naidu MU, Ratnakar KS. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci. 2000;66:2603-2611.
70. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199.
71. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555-562.
72. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-1444.
73. Reddi AS, Nimmagadda VR, Lefkowitz A, Kuo HR, Bollineni JS. Effect of antihypertensive therapy on renal injury in type 2 diabetic rats with hypertension. Hypertension. 2000;36:233-238.
74. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
75. Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int. 2002;61:2090-2098.
76. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhanser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1717.
77. Laverman GD, Remuzzi G. Antihypertensive therapy in chronic renal disease: a place for sympathicolytic agents? J Hypertens. 2003;21: 1625-1626.
78. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol. 2003;284:F1121-F1137.
79. Hoffman RP, Sinkey CA, Kienzle MG, Anderson EA. Muscle sympathetic nerve activity is reduced in IDDM before overt autonomic neuropathy. Diabetes. 1993;42:375-380.
80. Maliszewska-Scislo M, Scislo TJ, Rossi NF. Effect of blockade of endogenous angiotensin II on baroreflex function in conscious diabetic rats. Am J Physiol Heart Circ Physiol. 2003;284:H1601-H1611.
81. Matsuoka H. Protective role of renal nerves in the development of diabetic nephropathy. Diabetes Res. 1993;23:19-29.
82. Jyothirmayi GN, Alluru I, Reddi AS. Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. Hypertension. 1996;27: 1108-1114.
83. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12:602-605.
84. D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Impact of renal denervation on renal content of GLUT1, albuminuria and urinary TGF-beta1 in streptozotocin-induced diabetic rats. Auton Neurosci. 2003;104:88-94.
85. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens. 1994;7:84S-92S.
86. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23: 888-892.
87. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59: 1498-1509.
88. Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Friedman JE. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Kopetzky rat (SHROB). J Pharmacol Exp Ther. 1999;288:139-147.
89. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens. 2001;14:304S-309S.
90. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol. 1996;7:667-675.
91. Amann K, Greber D, Gharehbaghi H, Wiest G, Lange B, Ganten U, Mattfeldt T, Mall G. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens. 1992;5:76-83.
92. Barone FC, Campbell WG, Jr., Nelson AH, Feuerstein GZ. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertens. 1998;16:871-884.
93. Blezer EL, Nicolay K, Koomans HA, Joles JA. Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. Am J Hypertens. 2001;14:54-61.
94. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565.
95. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-1143.
96. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003; 107:2493-2498.
97. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
98. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26:861-865.
99. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens. 1992;5:437-443.
100. Pacca SR, de Azevedo AP, De Oliveira CF, De Luca IM, De Nucci G, Antunes E. Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J Cardiovasc Pharmacol. 2002;39: 201-207.